This report was first published by Endpoints News. To see the original version, click here
AbbVie began 2025 with a T cell engager deal in China, and it’s ending the year with another one.
The Chicago-area pharmaceutical giant is going to Zelgen Biopharmaceuticals for a clinical-stage T cell engager called ZG006, or alveltamig, according to a Shanghai Stock Exchange filing and local financial information websites.
您已阅读25%（415字），剩余75%（1270字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。